Shilpa Venkatachalam, PhD, and Courtney Wells, PhD, discuss the barriers to care, including lack of access and health care support, among patients with autoimmune diseases during the COVID-19 pandemic.
Researchers assessed the proportion and factors associated with serum urate testing after urate lowering therapy initiation among older adults with gout.
Study findings confirm hyperuricemia as an important prognostic factor for development of contrast-associated AKI.
Study findings suggest that asymptomatic hyperuricemia in CKD is tied with adverse outcomes.
Study results corroborate previous research suggesting a urate-lowering effect of SGLT2i.
DECT findings appeared more prognostic than serum uric acid levels alone.
Researchers studied the effect of gout on cardiovascular events, including CVD and heart failure, in a Black urban population.
Benzbromarone, a urate-lowering drug, appeared effective among patients with high serum uric acid levels who had no evidence of gout flares.
Patients with stage 3 chronic kidney disease are at increased risk for contrast-induced acute kidney injury.
Researchers evaluated effect of lowering serum urate levels to a target level on fracture risk among patients with gout.
